Antimycotic for Systematic Use
Conditions
Brief summary
A Randomized, Single-dose, Two-way Crossover Study to Evaluate Bioequivalence of Two Formulations of Voriconazole(200mg/Vial) After Intravenous Infusion of 200mg Voriconazole in Healthy Volunteers Under Fasting Conditions.
Interventions
DRUGVaway
Drug: Voriconazole. Pharmacokinetic study under fasting conditions
Sponsors
Yung Shin Pharm. Ind. Co., Ltd.
Study design
Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Single Group Assignment
Eligibility
Sex/Gender
ALL
Age
20 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
1. Healthy adult male or female subjects between 20-45 years of age (inclusive) at the screening visit. 2. Body weight within 80-120% of ideal body weight but not less than 45kg at the screening visit. * Ideal body weight (kg) = \[height (cm) - 80\] ´ 0.7 for male subjects * Ideal body weight (kg) = \[height (cm) - 70\] ´ 0.6 for female subjects 3. Acceptable medical history and physical examination including: * no particular clinically significant abnormalities in Electrocardiogram(ECG) results within six months prior to Period I dosing. * no particular clinical significance in general disease history within two months prior to Period I dosing. 4. Acceptable biochemistry determinations (within normal limits or considered by the investigator or physician to be of no clinical significance) within two months prior to Period I dosing, which includes ASpartate aminoTransferase (AST), ALanine aminoTransferase (ALT), Gamma-Glutamyl-Transpeptidase (g-GT), alkaline phosphatase, total bilirubin, albumin, glucose, BUN, uric acid, creatinine, total cholesterol, and triglyceride (TG). 5. Acceptable hematology (within normal limits or considered by the investigator or physician to be of no clinical significance) within two months prior to Period I dosing, which includes hemoglobin, hematocrit, red blood cell count, white blood cell count with differentials and platelets. 6. Acceptable urinalysis (within normal limits or considered by the investigator or physician to be of no clinical significance) within two months prior to Period I dosing, which includes pH, blood, glucose, ketones, bilirubin and protein. 7. Female of childbearing potential practicing an acceptable method of birth control for the duration of the study. 8. Have signed the written informed consent to participate in this study.
Exclusion criteria
1. A clinically significant disorder involving the cardiovascular, respiratory, hepatic, renal, gastrointestinal, immunologic, hematologic, endocrine or neurologic system(s) or psychiatric disease (as determined by the investigator). 2. A clinically significant illness or surgery within four weeks prior to Period I dosing (as determined by the investigator). 3. History of gastrointestinal obstruction, inflammatory bowel disease, gallbladder disease, pancreas disorder over last two years or history of gastrointestinal tract surgery over last five years. 4. History of kidney disease or urination problem over last two years deemed by the investigator to be clinically significant. 5. Known or suspected history of drug abuse within lifetime as judged by the investigator. 6. History of alcohol addiction or abuse within last five years as judged by the investigator. 7. History of allergic response(s) to voriconazole, any other drugs analogous to voriconazole, or any antibiotics. 8. Evidence of chronic or acute infectious diseases.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Ratio of AUC 0-t to AUC 0-∞ | 0 (pre-dose), 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 7.0, 8.0, 10, 12, 24, and 36 hours | The 90% confidence intervals of the geometric mean ratio (test/reference) for all parameters of voriconazole should fall within the range of 80.00% and 125.00%. |
| Peak concentration (Cmax) | 0 (pre-dose), 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 7.0, 8.0, 10, 12, 24, and 36 hours | The 90% confidence intervals of the geometric mean ratio (test/reference) for all parameters of voriconazole should fall within the range of 80.00% and 125.00%. |
| Time to reach peak concentration (Tmax) | 0 (pre-dose), 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 7.0, 8.0, 10, 12, 24, and 36 hours | The 90% confidence intervals of the geometric mean ratio (test/reference) for all parameters of voriconazole should fall within the range of 80.00% and 125.00%. |
| Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC 0-t) | 0 (pre-dose), 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 7.0, 8.0, 10, 12, 24, and 36 hours | The 90% confidence intervals of the geometric mean ratio (test/reference) for all parameters of voriconazole should fall within the range of 80.00% and 125.00%. |
| Area under the plasma concentration-time curve from time zero to infinity (AUC 0-∞) | 0 (pre-dose), 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 7.0, 8.0, 10, 12, 24, and 36 hours | The 90% confidence intervals of the geometric mean ratio (test/reference) for all parameters of voriconazole should fall within the range of 80.00% and 125.00%. |
| Elimination rate constant (入z) | 0 (pre-dose), 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 7.0, 8.0, 10, 12, 24, and 36 hours | The 90% confidence intervals of the geometric mean ratio (test/reference) for all parameters of voriconazole should fall within the range of 80.00% and 125.00%. |
| Terminal elimination half-life (t 1/2) | 0 (pre-dose), 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 7.0, 8.0, 10, 12, 24, and 36 hours | The 90% confidence intervals of the geometric mean ratio (test/reference) for all parameters of voriconazole should fall within the range of 80.00% and 125.00%. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Adverse events and incidences | 0 (pre-dose), 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 7.0, 8.0, 10, 12, 24, and 36 hours | Any symptom, sign or significant abnormal laboratory finding whether observed or reported during the course of the study will be reported as an adverse event (AE) whether or not it has causative relationship with the drug |
Countries
Taiwan
Outcome results
None listed